Drug therapy: EGFR antagonists in cancer treatment

被引：1683

作者：

Ciardiello, Fortunato ^{[1
]}

Tortora, Giampaolo ^{[2
]}

机构：

[1] Univ Naples 2, Div Med Oncol, Dept Expt & Clin Med & Surg F Magrassi & A Lanzar, I-80131 Naples, Italy

[2] Univ Naples Federico II, Div Med Oncol, Dept Mol & Clin Endocrinol & Oncol, Naples, Italy

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2008年 / 358卷 / 11期

关键词：

D O I：

10.1056/NEJMra0707704

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Functional activation of growth factors and receptors of the epidermal growth factor receptor (EGFR) family occurs in most epithelial-cell cancers, rendering EGFR a target for cancer treatment. This article discusses the mechanisms of action of EGFR inhibitors, their anticancer activity, and clinical issues concerning their use in the treatment of patients with cancer. Copyright © 2008 Massachusetts Medical Society. All rights reserved.

引用

页码：1160 / 1174

页数：15

共 114 条

[1]

Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO

[2]

2-H

[3]

AMADO RG, 2007, EURO J CANC S8, V5

[4]

[Anonymous], P AM SOC CLIN ONCOL

[5] Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin [J].

Baselga, J ;

Pfister, D ;

Cooper, MR ;

Cohen, R ;

Burtness, B ;

Bos, M ;

D'Andrea, G ;

Seidman, A ;

Norton, L ;

Gunnett, K ;

Falcey, J ;

Anderson, V ;

Waksal, H ;

Mendelsohn, J .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) :904-914

[6] Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck [J].

Baselga, J ;

Trigo, JM ;

Bourhis, J ;

Tortochaux, J ;

Cortés-Funes, H ;

Hitt, R ;

Gascón, P ;

Arnellal, N ;

Harstrick, A ;

Eckardt, A .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) :5568-5577

[7] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[8]

Belani CP, 2007, J CLIN ONCOL, V25, DOI 10.1200/JCO.2007.12.5435

[9] Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies [J].

Benvenuti, Silvia ;

Sartore-Bianchi, Andrea ;

Di Nicolantonio, Federica ;

Zanon, Carlo ;

Moroni, Mauro ;

Veronese, Silvio ;

Siena, Salvatore ;

Bardelli, Alberto .

CANCER RESEARCH, 2007, 67 (06) :2643-2648

[10] Symptom improvement in lung cancer patients treated with erlotinib: Quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21 (vol 24, pg 3831, 2006) [J].

Bezjak .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (01) :167-167

← 1 2 3 4 5 6 7 8 9 10 →